Firebrick Pharma is an Australian pharmaceutical developer, founded in 2012 by Dr Peter Molloy and Dr Stephen Goodall, with the mission to develop a nasal spray that killed all the germs (viruses or bacteria) responsible for respiratory infections such as the common cold.
Its first product, Nasodine® Nasal Spray, is in the final stages of development. Nasodine Nasal Spray contains the broad-spectrum antimicrobial agent, povidone-iodine. If approved, Nasodine will be the world's first nasal spray medicine that targets the cause of colds.
Firebrick Pharma listed on the ASX on 28 January 2022.